ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,593, issued on May 27, was assigned to Kelonia Therapeutics Inc. (Boston).
"Lymphocyte targeted lentiviral vectors" was invented by Molly R. Perkins (Milton, Mass.) and Kevin M. Friedman (Boston).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the p...